Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 10/24 10:00:00 pm
74.15 USD   -0.19%
10/24 GILEAD SCIENCES : to Present at the Credit Suisse 25th Annual Health..
10/24 GILEAD SCIENCES : Presents Results from Phase 3 Studies Evaluating S..
10/20 GILEAD SCIENCES : Jolley Asset Management buys $3,491,855 stake in G..
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : U.S. FDA Grants Priority Review for Truvada? for Reducing the Risk of Acquiring HIV Infection

share with twitter share with LinkedIn share with facebook
share via e-mail
02/14/2012 | 01:38am CEST

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 13, 2012-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada® (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults. Truvada was approved by the FDA in 2004 for the treatment of HIV-1 infection and is currently the most-prescribed antiretroviral treatment in the United States.

The FDA grants priority review status to drug candidates that provide major advances in treatment or provide a treatment where no adequate therapy exists. Gilead submitted the Truvada for PrEP sNDA on December 15, 2011. The FDA has set a target review date for Truvada for PrEP under the Prescription Drug User Fee Act (PDUFA) of June 15, 2012. The agency has also indicated that Truvada for PrEP will be discussed at the FDA Antiviral Drugs Advisory Committee meeting scheduled in May.

If the sNDA is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV. The sNDA is based on the results of two large placebo-controlled trials of Truvada as PrEP sponsored by the U.S. National Institutes of Health and the University of Washington. Several other clinical studies support the use of Truvada for HIV risk reduction.

Truvada is not currently indicated to reduce the risk of HIV infection.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that the FDA may not approve Truvada for HIV-1 risk reduction, and any approval, if granted, may have significant limitations on its use. Additionally, even if approved, physicians may be reluctant to prescribe the product for HIV risk reduction, and payers may be reluctant to approve or provide reimbursement for the product for HIV risk reduction. As a result, there may not be significant use of Truvada as a risk reduction tool. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. . www.Truvada.com

Truvada is a registered trademark of Gilead Sciences, Inc.

For more information on Gilead Sciences, please visit the company's website at or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936 (Investors)
Cara Miller, 650-522-1616 (Media)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
10/24 GILEAD SCIENCES : to Present at the Credit Suisse 25th Annual Healthcare Confere..
10/24 GILEAD SCIENCES : Presents Results from Phase 3 Studies Evaluating Switching to ..
10/20 GILEAD SCIENCES : Patent Issued for Methods of Treating Patients Co-Infected wit..
10/20 GILEAD SCIENCES : Jolley Asset Management buys $3,491,855 stake in Gilead Scienc..
10/20 GILEAD SCIENCES : Announces SVR12 Rates From Four Phase 3 Studies of a Once-Dail..
10/20 GILEAD SCIENCES : Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) i..
10/14 GILEAD SCIENCES : Creative Planning buys $25,314,133 stake in Gilead Sciences
10/10 GILEAD SCIENCES : Private Asset Management Inc buys $8,511,601 stake in Gilead S..
10/07 GILEAD SCIENCES : Kempner Capital Management adds Gilead Sciences to its portfol..
10/04DJFDA Warns on Hepatitis C Drugs
More news
Sector news : Bio Therapeutic Drugs
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/24 Cheap Stocks Vs. Value Traps - Update And Watchlist
10/24 Manic Monday Markets - Propped Up Futures Give Us Another Opportunity
10/24 BIOTECH FORUM DAILY DIGEST : Election Worries Overblown? Spotlight On Akorn
10/21 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Established Biotechnology Stocks
10/21 Why You (And Another Company) Should Buy Gilead - Dividend Sensei
Financials ($)
Sales 2016 30 392 M
EBIT 2016 20 100 M
Net income 2016 14 611 M
Debt 2016 2 884 M
Yield 2016 2,49%
P/E ratio 2016 6,96
P/E ratio 2017 6,66
EV / Sales 2016 3,32x
EV / Sales 2017 3,28x
Capitalization 98 037 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 103 $
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-26.72%98 037
AMGEN, INC.-2.20%118 623
ACTELION LTD17.34%16 178
More Results